Tumour-specific Antibodies in Human Malignant Melanoma and their Relationship to the Extent of the Disease

Mg, Lewis; Rl, Ikonopisov; Rc, Nairn; Tm, Phillips; Gh, Fairley; Dc, Bodenham; Alexander, Peter

doi:10.1136/bmj.3.5670.547

Cited by 365 publications

(104 citation statements)

References 12 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the 2 reactive patients with Stage III cancer initially had a minimal tumour burden and, as the tumour burden increased, showed a loss of reactivity. By other in vitro assays of CMI or humoral immunity, a diminution of tumour-specific immunity in melanoma patients with disseminated disease has been reported (Morton et al, 1968;Lewis et al, 1969;Currie and Basham, 1972;Cochran et al, 1973;Heppner et al, 1973;and Unsgaard and O'Toole, 1975 Coggin et al, 1974). We suggested that soluble tumour antigen in the microenvironment of the tumour prevents rejection (Thomson, 1975) and, as the tumour load increases, sufficient tumour antigen is released systemically to neutralize systemic anti-tumour immunity.…”

Section: Discussionmentioning

confidence: 95%

“…In the present study we also observed that the majority of buffy coat PBL adhered to the glass in the absence of serum (protein). Leucocytes from control subjects showed non-specific non-adherence with the addition of tumour extracts, and the number of non-adherent cells (00 nonadherence) was Lewis et al (1969) showed, by indirect membrane immunofluorescence, that serum from melanoma patients reacted against the autologous melanoma cell surfaces and lacked significant crossreactivity with allogeneic melanoma. Bodurtha et al (1975), by a complementdependent cytotoxicity assay for antibodies to malignant melanoma, confirmed the findings of Lewis et al (1969).…”

Section: Discussionmentioning

confidence: 99%

“…Leucocytes from control subjects showed non-specific non-adherence with the addition of tumour extracts, and the number of non-adherent cells (00 nonadherence) was Lewis et al (1969) showed, by indirect membrane immunofluorescence, that serum from melanoma patients reacted against the autologous melanoma cell surfaces and lacked significant crossreactivity with allogeneic melanoma. Bodurtha et al (1975), by a complementdependent cytotoxicity assay for antibodies to malignant melanoma, confirmed the findings of Lewis et al (1969). Other investigators, however, have shown crossreactivity with membrane immunofluorescence and cell-mediated assays (Morton et al, 1968;Currie et al, 1971;Nairn et al, 1972;and Hollinshead et al, 1974).…”

Section: Discussionmentioning

confidence: 99%

“…responses to tumour are observed with tumour progression (Lewis et al, 1969;Morton, Eilber and Malmgren, 1971;deVries et al, 1972;Cochran et al, 1973;. Halliday and Miller (1972) developed an assay of cell-mediated anti-tumour immunity, called leucocyte adherence inhibition (LAI).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition

Marti¹,

Thomson²

1976

Br J Cancer

View full text Add to dashboard Cite

Summary.-Tumour antigen-induced inhibition of leucocyte adherence was modified for use in glass test tubes (Tube LAI assay) for the study of cell-mediated antitumour immunity to human malignant melanoma. Peripheral blood leucocytes (PBL) of 20 out of 25 patients (80%) with active malignant melanoma responded to an extract of malignant melanoma with LAI, whereas only 4.5%o of 475 control subjects showed a response. The malignant melanoma patients reacted to both allogeneic and autologous extracts of malignant melanoma which indicates a common cross-reacting antigen. Malignant melanoma patients did not respond to unrelated tumour extracts. The LAI was mediated by PBL (monocytes) " armed" with cytophilic anti-tumour antibody specific for the sensitizing tumour antigen.The anti-tumour response of the malignant melanoma patients was dependent on the stage of the cancer, and 11 out of 13 Stage I patients had a positive NAI, whereas patients with disseminated cancer had decreased response. The diminished LAI in patients with large tumour burdens appeared to be the result of release of tumour antigen systemically. Also, surgery and chemotherapy depressed LAI. Although LAI was depressed after surgical excision of the cutaneous melanoma, most patients showed LAI 1-3 months later. Tumour-free melanoma patients monitored for one year by the Tube LAI assay showed a decline in their anti-tumour immunity 5-6 months after surgery. The NAI was low or negative after the 8th post-surgical month in tumour-free patients. Patients with residual malignant melanoma showed persistent or recurrent LAI after the 8th post-surgical month. LAI reactivity monitored after " curative " surgery for malignant melanoma may assist in determining whether the patient is tumour-free or has a recurrence.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition

Marti¹,

Thomson²

1976

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Similarly, the technique described here for isolating and purifying tumour specific antigenic determinants of chemically induced tumours may offer the prospects of chemically defining these determinants and should facilitate the studY of their role in the host-tumour relationship. In addition, this method should be applicable to the isolation and purification of water-soluble human tumour antigens (GCutterman et al, 1972) capable of evoking a specific humoral immune response (Bias et al, 1972;Lewis et al, 1969).…”

Section: Preliminary Purification By Gel Exclusion Chromatogr-aphymentioning

confidence: 99%

Radioimmunoassay of Tumour Specific Transplantation Antigen of a Chemically Induced Rat Sarcoma: Circulating Soluble Tumour Antigen in Tumour Bearers

Thomson¹,

Sellens²,

Eccles³

et al. 1973

Br J Cancer

View full text Add to dashboard Cite

Summary.-The tumour specific transplantation antigen (TSTA) from a chemically induced rat sarcoma has been isolated as an electrophoretically homogeneous soluble material by affinity chromatography using a Sepharose bound antibody raised to the tumour in syngeneic rats. The TSTA is specific for the particular tumour used (the MC-1 sarcoma) and does not cross-react with material extracted from other rat sarcomata. In addition, a material with different physicochemical properties which cross-reacted with different sarcomata was also eluted from the antibody column and this may be the previously identified onco-embryonic antigen (OEAl) which is immunogenic in the syngeneic host.The purified TSTA labelled with 125I was used in a radioimmunoassay which detected soluble TSTA in rats bearing a MC-1 sarcoma. The assay shows that tumour transplantation is associated with a persisting release of soluble antigen into the circulation. This antigenic burden is present continuously and renewed as long as the tumour mass exists.

show abstract

Antibodies Against the Cytoplasm of Human Epidermal Cells

Bystryn¹

1973

Arch Dermatol

View full text Add to dashboard Cite

Tumour-specific Antibodies in Human Malignant Melanoma and their Relationship to the Extent of the Disease

Cited by 365 publications

References 12 publications

Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition

Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition

Radioimmunoassay of Tumour Specific Transplantation Antigen of a Chemically Induced Rat Sarcoma: Circulating Soluble Tumour Antigen in Tumour Bearers

Antibodies Against the Cytoplasm of Human Epidermal Cells

Contact Info

Product

Resources

About